COVID-19 vaccine trial shows positive results
2020-05-19 at 07:21
An experimental vaccine against the coronavirus have shown encouraging results in very early testing, triggering hoped-for immune responses in eight healthy, middle-aged volunteers.
Study volunteers given either a low or medium dose of the vaccine by Cambridge, Massachusetts-based Moderna Inc. had antibodies similar to those seen in people who have recovered from COVID-19.
In the next phase of the study, led by the US National Institutes of Health, researchers will try to determine which dose is best for a definitive experiment that they aim to start in July.
In all, 45 people have received one or two shots of the vaccine, which was being tested at three different doses.
The kind of detailed antibody results needed to assess responses are only available on eight volunteers so far.
The vaccine seems safe, the company said, but much more extensive testing is needed to see if it remains so.
A high dose version is being dropped after spurring some short-term side effects.
The results have not been published and are only from the first of three stages of testing that vaccines and drugs normally undergo.
Worldwide, about a dozen vaccine candidates are in the first stages of testing or nearing it.
Health officials have said that if all goes well, studies of a potential vaccine might wrap up by very late this year or early next year.